The coronavirus has gotten way out of hand.
Over the weekend, the U.S. saw another 83,000 cases, and numbers are still climbing.
Hospitals are running near capacity.
In Texas, Judge Ricardo Samaniego issued a curfew saying that hospitals and health workers are now “overwhelmed and exhausted,” as quoted by CNBC.
Former FDA Commissioner Dr. Scott Gottlieb just said, “We are likely to see a very dense epidemic. I think we are right now at the cusp of what is going to be exponential spread in parts of the country.”
What could make the situation far worse is winter.
“The coronavirus crisis may be entering a more dangerous period in the U.S. as the country heads toward winter season and temperatures fall,” says Andy Slavitt, former acting administrator at the Centers for Medicare and Medicaid Services, as noted by CNBC.
“We’re seeing much higher growth in cases all over the northern part of the U.S., and the northern part of the U.S. is just a teaser for what happens when it gets cold throughout the rest of the country, as it is going to shortly,” he added.
That being the case, some of the top stocks to consider include:
Teladoc Health (TDOC)
Even at $220 a share, TDOC is still a solid opportunity, as telehealth demand explodes. After all, “The critical need for social distancing among physicians and patients will drive unprecedented demand for telehealth, which involves the use of communication systems and networks to enable either a synchronous or asynchronous session between the patient and provider,” said Victor Camlek, healthcare principal analyst at Frost & Sullivan.
Zoom Video Communications (ZM)
With another wave of the virus making its way around the world, video conferencing will be under big demand for students and businesses.
Video conferencing has become a big part of life for millions working and schooling from home. In fact, according to Reuters, “Video-conferencing platforms, once used mostly as a technological substitute for in-person meetings, became a vital part of day-to-day life this year for people stuck at home under coronavirus restrictions, be it for work, school or socializing.”
Moderna Inc. (MRNA)
CEO Stephane Bancel said the U.S. government could authorize emergency use of the company’s vaccine by December. That is, if the company can produce positive interim results in November from its clinical trial.
According to The Wall Street Journal:
The company must “monitor the safety of at least half of the study subjects for two months after vaccination before it can seek an authorization for emergency use. Moderna was likely to reach that threshold in late November. If Moderna files for an emergency use authorization soon after, the Food and Drug Administration may take a few weeks to review the application before deciding in December.”